白蛋白结合型与常规PSMA配体联合161Tb:生物分布、剂量学与临床前治疗研究
本研究在PC-3 PIP荷瘤小鼠中比较161Tb与177Lu标记的SibuDAB和PSMA-I&T的剂量学与疗效。白蛋白结合型SibuDAB血液驻留时间更长、肿瘤摄取更高(注射后24小时62%-69%ID/g vs 30%-35%ID/g)。161Tb标记物因肿瘤吸收剂量较177Lu高约40%而疗效更优,未观察到明显不良事件。
要点
- SibuDAB因白蛋白结合特性,注射后24小时肿瘤摄取达62%-69%ID/g,高于PSMA-I&T的30%-35%ID/g。
- [161Tb]Tb-SibuDAB因肿瘤吸收剂量高4倍,抑制肿瘤生长比[161Tb]Tb-PSMA-I&T更有效。
- 在所用全部活度下,161Tb标记配体疗效均优于177Lu标记对应物,与肿瘤剂量高约40%一致。
核心结论
- 本研究数据表明161Tb联合SibuDAB在前列腺癌放射性配体治疗中具有前景。
- 未来基于161Tb的放射性配体治疗临床研究将揭示161Tb相对于177Lu的潜在临床获益。
研究设计与样本
- 在PC-3 PIP荷瘤小鼠中开展体外实验、生物分布、显像与治疗研究,比较[161Tb]Tb-SibuDAB和[161Tb]Tb-PSMA-I&T,并以177Lu标记对应物用于剂量计算与疗效比较。
- 通过体重、血浆参数、血细胞计数及相关器官组织学监测放射性配体治疗在小鼠中的耐受性。
主要发现
- PSMA靶向放射性配体无论标记161Tb还是177Lu,体外数据相似且组织分布特征相当。
- 因白蛋白结合特性,[161Tb]Tb/[177Lu]Lu-SibuDAB血液驻留时间延长,注射后24小时肿瘤摄取为62%-69%ID/g,高于[161Tb]Tb/[177Lu]Lu-PSMA-I&T的30%-35%ID/g。
- [161Tb]Tb-SibuDAB抑制肿瘤生长比[161Tb]Tb-PSMA-I&T更有效,归因于其肿瘤吸收剂量高4倍。
- 在所用任一活度下,161Tb标记配体疗效均优于177Lu标记对应物,与161Tb肿瘤剂量较177Lu高约40%一致。
- 在给定实验条件下未观察到明显不良事件。
关键数值与推荐
- [161Tb]Tb/[177Lu]Lu-SibuDAB注射后24小时肿瘤摄取为62%-69%ID/g,[161Tb]Tb/[177Lu]Lu-PSMA-I&T为30%-35%ID/g。
- [161Tb]Tb-SibuDAB的肿瘤吸收剂量较[161Tb]Tb-PSMA-I&T高4倍。
- 161Tb的肿瘤剂量较177Lu高约40%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The favorable decay characteristics of 161Tb attracted the interest of clinicians in using this novel radionuclide for radioligand therapy (RLT). 161Tb decays with a similar half-life to 177Lu, but beyond the emission of β--particles and γ-rays, 161Tb also emits conversion and Auger electrons, which may be particularly effective to eliminate micrometastases. The aim of this study was to compare the dosimetry and therapeutic efficacy of 161Tb and 177Lu in tumor-bearing mice using SibuDAB and PSMA-I&T, which differ in their blood residence time and tumor uptake. Methods: [161Tb]Tb-SibuDAB and [161Tb]Tb-PSMA-I&T were evaluated in vitro and investigated in biodistribution, imaging, and therapy studies using PC-3 PIP tumor-bearing mice. The 177Lu-labeled counterparts served for dose calculations and comparison of therapeutic efficacy. The tolerability of RLT in mice was monitored on the basis of body mass, blood plasma parameters, blood cell counts, and the histology of relevant organs and tissues. Results: The prostate-specific membrane antigen (PSMA)-targeting radioligands, irrespective of whether labeled with 161Tb or 177Lu, showed similar in vitro data and comparable tissue distribution profiles. As a result of the albumin-binding properties, [161Tb]Tb/[177Lu]Lu-SibuDAB had an enhanced blood residence time and higher tumor uptake (62%-69% injected activity per gram at 24 h after injection) than [161Tb]Tb/[177Lu]Lu-PSMA-I&T (30%-35% injected activity per gram at 24 h after injection). [161Tb]Tb-SibuDAB inhibited tumor growth more effectively than [161Tb]Tb-PSMA-I&T, as can be ascribed to its 4-fold increased absorbed tumor dose. At any of the applied activities, the 161Tb-based radioligands were therapeutically more effective than their 177Lu-labeled counterparts, as agreed with the approximately 40% increased tumor dose of 161Tb compared with that of 177Lu. Under the given experimental conditions, no obvious adverse events were observed. Conclusion: The data of this study indicate the promising potential of 161Tb in combination with SibuDAB for RLT of prostate cancer. Future clinical studies using 161Tb-based RLT will shed light on a potential clinical benefit of 161Tb over 177Lu.
引用
- Tschan VJ, Busslinger SD, Bernhardt P, et al. Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy. J Nucl Med. 2023. PMID: 37442604. doi:10.2967/jnumed.123.265524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。